AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...
Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close o...
The protein Asc-1 serves as the gateway (either for entry or exit) for fundamental amino acids involved in cognitive processes. A new study now unveils its structure and mechanism of action.
Laminar Pharma opens a new financing round of up to seven million euros. The objective is to finish financing the development of its drug LAM561 against the most aggressive and common brain cancer, gl...